In Vivo. 2005 Jan-Feb;19(1):233-6. Related Articles, Links
Anti-tumor activities of four chelating agents against human
neuroblastoma cells.
Shen L, Zhao HY, Du J, [censored] F.
National Isotope Center of Engineering and Technology, China Institute
of Atomic Energy, Beijing 102413, China. [email hidden]
BACKGROUND: Iron deprivation may be a therapeutic strategy for cancer.
It can be achieved by using iron chelators. In this investigation,
anti-neuroblastoma activities of a novel ferric chelator 2LL together
with DFO, EDTA and DTPA were evaluated. MATERIALS AND METHODS: SH-Sy5y
cells were cultured at 37 degrees C in 5% CO2/95% air in DMEM
containing 10% fetal bovine serum. The cells were seeded in 96-well
microtiter plates overnight. Then, chelating agents were added into the
wells. After 48-hour incubation, viabilities were measured using the
MTT method. RESULTS: DTPA had an IC50 value between 60-100 microM; DFO
produced about 40% inhibiting effect at 150 microM; 2LL and EDTA
displayed about 10% inhibiting effect at high concentrations.
CONCLUSION: For SH-Sy5y cells, DTPA showed the strongest inhibiting
effect, DFO displayed a moderate inhibiting effect, while 2LL and EDTA
produced minor inhibition. To develop iron chelators as powerful
anti-cancer agents is still a challenging task.
PMID: 15796180 [PubMed - in process]
--------------------------------------------------------------------------------
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://herbivore.7h.com